Skip to main content

Advertisement

Fig. 6 | Genome Medicine

Fig. 6

From: A genome-wide siRNA screen identifies a druggable host pathway essential for the Ebola virus life cycle

Fig. 6

Effects of teriflunomide on infectious EBOV titres. a Effects of teriflunomide on a luciferase-expressing EBOV. HEK293 or VeroE6 cells were infected with a recombinant EBOV expressing firefly luciferase (FF) at an MOI of 0.05 in the presence of the indicated amounts of teriflunomide. In parallel, an ATP-based cell viability assay was performed using UltraGlo luciferase activity as a readout. Forty-eight hours post infection, reporter activity was measured. Means and standard deviations of 8 biological replicates from 2 independent experiments are shown. b Effect of teriflunomide on infectious titers of EBOV. Susceptible cells were infected with a GFP-expressing EBOV at an MOI of 0.05 in the presence of the indicated amounts of teriflunomide (TF). Forty-eight hours post infection, supernatants were harvested and titers determined by TCID50 analysis. Means and standard deviations from 3 independent experiments are shown

Back to article page